{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'Natl Acad Sci U S A. 2010;107(32):14351-6 10.1073/pnas.1001072107. 2922538', '22.', 'Sundy J. S. Progress in the pharmacotherapy of gout. Curr Opin Rheumatol. 2010;22(2):188-93.', '10.1097/BOR.0b013e3283369014.', '23.', 'Simkin P. A. Management of gout. Ann Intern Med. 1979;90(5):812-6.', '24.', 'Emmerson B. T. The management of gout. N Engl J Med. 1996;334(7):445-51.10.1056/nejm199602153340707.', '25.', 'Schumacher H. R. Crystal-induced arthritis: an overview. Am J Med. 1996;100(2a):46s-52s', '26.', 'Perez-Ruiz F., Calabozo M., Pijoan J. I., Herrero-Beites A. M., Ruibal A. Effect of urate-lowering therapy on the velocity of', 'size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47(4):356-60. 10.1002/art.10511.', '27.', 'Wang K., Zhang H., i Y., Wei Q., Li H., Yang Y., Lu Y. Efficacy of mycophenolate mofetil versus azathioprine after renal', 'transplantation: a systematic review. Transplant Proc. 2004;36(7):2071-2.10.1016/j.transproceed.2004.07.059.', '28.', 'Rathi M., Goyal A., Jaryal A., Sharma A., Gupta P. K., Ramachandran R., Kumar V., Kohli H. S., Sakhuja V., Jha V., Gupta K. L.', 'Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus', 'nephritis. Kidney Int. 2015. 10.1038/ki.2015.318.', '29.', 'Noureldeen T., Albekioni Z., Machado L., Muddana N., Marcus R. J., Hussain S. M., Sureshkumar K. K. Alemtuzumab', 'induction and antibody-mediated rejection in kidney transplantation. Transplant Proc. 2014;46(10):3405-7', '10.1016/j.transproceed.2014.08.037.', '30.', 'Meriggioli M. N., Ciafaloni E., Al-Hayk K. A., Rowin J., Tucker-Lipscomb B., Massey J. M., Sanders D. B. Mycophenolate', 'mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003;61(10):1438-40.', '31.', 'Krieckaert C.L., Bartelds G. M., Lems W. F., Wolbink G. J. The effect of immunomodulators on the immunogenicity of TNF-', 'blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010;12(5):217. 10.1186/ar3147.2991013', '32.', 'Maneiro J. R., Salgado E., Gomez-Reino J. J. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in', 'chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med.', '2013;173(15):1416-28.10.1001/jamainternmed.2013.7430.', '33.', 'Bartelds G. M., Krieckaert C. L., Nurmohamed M. T., van Schouwenburg P. A., Lems W. F., Twisk J. W., Dijkmans B. A.,', 'Aarden L., Wolbink G. J. Development of antidrug antibodies against adalimumab and association with disease activity and', 'treatment failure during long-term follow-up. JAMA. 2011;305(14):1460-8. 10.1001/jama.2011.406', '34.', 'Dervieux T., Weinblatt M. E., Kivitz A., Kremer J. M. Methotrexate polyglutamation in relation to infliximab', 'pharmacokinetics in rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):908-10. 10.1136/annrheumdis-2012-202591.', '35.', 'Berhanu A. A., Krasnokutsky S., Keenan R. T., Pillinger M. H. Pegloticase failure and a possible solution: Immunosuppression', 'to', 'prevent intolerance and inefficacy in patients with gout. Semin Arthritis Rheum. 2016. 10.1016/j.semarthrit.2016.09.007.', '36.', 'Krieckaert C. L., Nurmohamed M. T., Wolbink G. J. Methotrexate reduces immunogenicity in adalimumab treated', 'rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis.2012;71(11):1914-5.10.1136/annrheumdis-', '2012-201544.', '37.', 'Jani Meghna, Barton Anne, Warren Richard B., Griffiths Christopher E. M., Chinoy Hector. The role of DMARDs in reducing', 'the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford, England). 2014;53(2):213-', '22. 10.1093/rheumatology/ket260.', '38.', 'Rovin B. H., Furie R., Latinis K., Looney R. J., Fervenza F. C., Sanchez-Guerrero J., Maciuca R., Zhang D., Garg J. P., Brunetta', 'P., Appel G. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis', 'Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-26 10.1002/art.34359.', '39.', 'Ginzler E. M., Dooley M. A., Aranow C., Kim M. Y., Buyon J., Merrill J. T., Petri M., Gilkeson G.S., Wallace D.J., Weisman M.', 'H., Appel G. B. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med.', '2005;353(21):2219-28 10.1056/NEJMoa043731.', '40.', 'Kamanamool N., McEvoy M., Attia J., Ingsathit A., Ngamjanyaporn P., Thakkinstian A. Efficacy and adverse events of', 'mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-', 'analysis. Medicine (Baltimore). 2010;89(4):227-35. 10.1097/MD.0b013e3181e93d00.', '41.', 'Lee Y. H., Song G. G. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction', 'therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lupus. 2015;24(14):1520-8', '10.1177/0961203315595131.', '42.', 'Sollinger H. W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients.', 'U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60(3):225-32.', '43.', 'Srinivas T. R., Kaplan B., Meier-Kriesche H. U. Mycophenolate mofetil in solid-organ transplantation. Expert Opin', 'Pharmacother. 2003;4(12):2325-45. 10.1517/14656566.4.12.2325.', '44.', 'Magro-Checa C., Zirkzee E. J., Huizinga T. W., Steup-Beekman G. M. Management of Neuropsychiatric Systemic Lupus', 'Erythematosus: Current Approaches and Future Perspectives. Drugs. 2016;76(4):459-83. 10.1007/s40265-015-0534-3.', 'Pmc4791452', '47']\n\n###\n\n", "completion": "END"}